Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

47Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Methods: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Results: Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. Conclusions: This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.

Author supplied keywords

References Powered by Scopus

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

5504Citations
N/AReaders
Get full text

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

3454Citations
N/AReaders
Get full text

Tumor angiogenesis

2028Citations
N/AReaders
Get full text

Cited by Powered by Scopus

ImmunoPET: Concept, Design, and Applications

333Citations
N/AReaders
Get full text

Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: What can we learn from initial clinical trials?

162Citations
N/AReaders
Get full text

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

144Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Bahce, I., Huisman, M. C., Verwer, E. E., Ooijevaar, R., Boutkourt, F., Vugts, D. J., … Smit, E. F. (2014). Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Research, 4(1), 1–7. https://doi.org/10.1186/s13550-014-0035-5

Readers' Seniority

Tooltip

Researcher 13

48%

PhD / Post grad / Masters / Doc 12

44%

Professor / Associate Prof. 2

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 20

74%

Chemistry 3

11%

Pharmacology, Toxicology and Pharmaceut... 2

7%

Agricultural and Biological Sciences 2

7%

Save time finding and organizing research with Mendeley

Sign up for free